Board Member
GeneDx Holdings Corp. (WGS)Equibles does not estimate personal net worth.
Get an email with a short summary when Twist Bioscience Corp publishes a filing, an earnings call transcript or a press release.
Get TWST alertsEmily Leproust is recorded as CEO at Twist Bioscience Corp (TWST) and Board Member at GeneDx Holdings Corp. (WGS) since January 1, 2020. The newest filing on record that lists Emily Leproust as CEO at Twist Bioscience Corp (TWST) is dated January 6, 2026. The newest filing on record that lists Emily Leproust as Board Member at GeneDx Holdings Corp. (WGS) is dated April 30, 2026. The proxy statement of Twist Bioscience Corp reports total compensation of $13,781,570 for Emily Leproust in fiscal 2025, including a base salary of $720,000. Disclosed compensation is on record for 8 fiscal years. Emily Leproust has spoken on 26 earnings calls and 4 other investor events across 1 company, most recently for Twist Bioscience Corp on September 15, 2026. Twist Bioscience Corp is classified in the Biotechnology industry within the Healthcare sector. GeneDx Holdings Corp. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Twist Bioscience Corp includes Adam Laponis (CFO), Patrick Finn (COO), Patrick Weiss (COO) and 7 others.
“Thanks for the invitation and the introduction. so yes at Twist we built a technology that miniaturizes the chemistry of making DNA so DNA has four letters A, C, G, T and we have a printer that has four color print heads the A, the C, the G and the T and then we print on silicon chip in the square the size of two…”
“On slide three, you will see that this morning we reported our 14th quarter of consecutive growth with record revenue of $118.4 million, growth of 23% year-over-year.”
“It's my great pleasure to tell you more about TWIST and start by saying that I'll be making some forward-looking statements. So at TWIST, we are a company that builds DNA from scratch and provides customized solutions to companies on the vertical continuum.”
“I'm glad to welcome our CTO, Si-Wan Chen, who's going to tell us some of our strategy. Thank you, Si-Wan.”
“On slide 19, as we look ahead, we remain focused on delivering consistent measurable growth designed to scale over time. We see strong momentum across the portfolio, with continued growth in DNA synthesis and protein solutions, increasing adoption in AI-enabled discovery, and a return to growth in MGS.”
2020-01-01–present
Last confirmed April 30, 2026
Start not stated–present
Last confirmed January 6, 2026
Start not stated–2022-01-04
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO
Diagnostics & Research · Healthcare
Board Member
2020-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Twist Bioscience Corp (TWST) | Chief Executive Officer and Chair of the Board | $720,000 | $13,781,570 |
| 2024 | Twist Bioscience Corp (TWST) | Chief Executive Officer and Chair of the Board | $685,000 | $7,620,611 |
| 2023 | Twist Bioscience Corp (TWST) | Chief Executive Officer and Chair of the Board | $685,000 | $7,998,637 |
| 2022 | Twist Bioscience Corp (TWST) | Chief Executive Officer and Chair of the Board | $665,000 | $5,917,663 |
| 2021 | Twist Bioscience Corp (TWST) | Chief Executive Officer and Chair of the Board | $590,083 | $1,281,593 |
| 2020 | Twist Bioscience Corp (TWST) | Chief Executive Officer and Chair of the Board | $519,167 | $7,436,572 |
| 2019 | Twist Bioscience Corp (TWST) | President, Chief Executive Officer and Chair | $477,042 | $8,126,157 |
| 2018 | Twist Bioscience Corp (TWST) | President, Chief Executive Officer and Chair | $362,250 | $524,674 |
